The Role of Uridine Adenosine Tetraphosphate in the Vascular System by Matsumoto, Takayuki et al.
Hindawi Publishing Corporation
Advances in Pharmacological Sciences
Volume 2011, Article ID 435132, 7 pages
doi:10.1155/2011/435132
Review Article
The Role of UridineAdenosine Tetraphosphate in
theVascularSystem
Takayuki Matsumoto,1,2 RitaC.Tostes,3 and R. Clinton Webb1
1Department of Physiology, Georgia Health Sciences University, 1120 Fifteenth Street, CA-3135, Augusta, GA 30912-3000, USA
2Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, 2-4-41 Ebara, Shinagawa-ku,
Tokyo 142-8501, Japan
3Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, 14049-900 Sao Paulo, SP, Brazil
Correspondence should be addressed to Takayuki Matsumoto, t-matsu@hoshi.ac.jp
Received 9 August 2011; Accepted 21 September 2011
Academic Editor: Masahiro Oike
Copyright © 2011 Takayuki Matsumoto et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The endothelium plays a pivotal role in vascular homeostasis, and endothelial dysfunction is a major feature of cardiovascular
diseases, such as arterial hypertension, atherosclerosis, and diabetes. Recently, uridine adenosine tetraphosphate (Up4A) has been
identiﬁed as a novel and potent endothelium-derived contracting factor (EDCF). Up4A structurally contains both purine and
pyrimidinemoieties,whichactivatepurinergicreceptors.Thereisanaccumulating bodyofevidencetoshowthatUp4Amodulates
vascular function by actions on endothelial and smooth muscle cells. In this paper, we discuss the eﬀects of Up4Ao nv a s c u l a r
function and a potential role for Up4A in cardiovascular diseases.
1.Introduction
A healthy endothelium expresses and releases various
molecules, which aid to maintain vascular structure and
homeostasis [1, 2]. Endothelial cells actively regulate basal
vascular tone and vascular reactivity in physiological and
pathophysiological conditions, by responding to mechanical
forces (e.g., shear stress) and neurohumoral mediators with
the release of a variety of relaxing factors [endothelium-
derived relaxing factors (EDRFs)] or contracting factors
[endothelium-derived contracting factors (EDCFs)] [3–5].
Endothelial dysfunction plays a key role in the initiation
and development of both macro- and microangiopathy in
patients with arterial hypertension, inﬂammatory-associated
diseases (atherosclerosis), hypercholesterolemia, stroke, dia-
betes, as well as in animal models of these diseases [4–
12]. The mechanisms that regulate the balance between
EDRFsandEDCFsareimportantforvascularhealth.Mecha-
nisms that increase EDRFs and/or decrease the release
and/or bioavailability of EDCFs are promising drug targets
to alleviate the damage caused by endothelial dysfunc-
tion. So far, several factors are known as EDCFs such as
endothelin-1, angiotensin II, vasoconstrictor prostanoids,
and reactive oxygen species [4, 5, 13].
The dinucleotide uridine adenosine tetraphosphate
(Up4A) (Figure 1) was identiﬁed by Jankowski et al. [14]
as a novel potent EDCF. Up4A was isolated from the
supernatant of stimulated human endothelium and was
identiﬁed by mass spectrometry. Up4A is released from the
endothelium in response to acetylcholine (ACh), the calcium
ionophore (A23187), endothelin-1, adenosine triphosphate
(ATP), uridine triphosphate (UTP), and mechanical stress.
Therefore, Up4A can contribute to vascular regulation as
an endothelium-derived factor [14]. Up4A plasma concen-
trations detected in healthy subjects are high enough to
cause vasoconstriction [14]. Moreover, Up4A is the ﬁrst
dinucleotide found in living organisms that contains both
purine and pyrimidine moieties (Figure 1).
Purinergic signaling is important not only in short-term
regulation of vascular tone but also in long-term regulation
of vascular remodeling (i.e., vascular cell proliferation,
migration, and death) [15–21]. Moreover, dinucleotides
containing two purine moieties are known, and their role in


















































Figure 1: Up4A and vascular tone. Details are shown in the text. Up4A may directly or indirectly activate L-type Ca2+ channel. NO: nitric
oxide;eNOS:endothelialnitricoxidesynthase;EC:endothelialcell;SMC:smoothmusclecell;SR:sarcoplasmicreticulum;ERK:extracellular
signal regulated kinase.
However, the vasoactivity of Up4Am a yd i ﬀer from those of
dinucleotides exclusively containing purines [20, 24]. There-
fore, Up4A can play a functional role in the vascular system
both under physiological and pathophysiological conditions.
This paper focuses on the eﬀects of Up4A on vascular
tone and its putative role on vascular function.
2. Up4A andVascular Tone under
Physiological Conditions
Several reports demonstrated that Up4A modulates vasomo-
tor activity in vessels from nondisease animal models using
both in vitro (i.e., perfusion or myograph system) and in vivo
techniques (Table 1, Figure 1). Since Up4A possesses both
purine and pyrimidine moiety, these studies mainly focus on
the relationship between Up4A and purinoceptor signaling.
Purinoceptors have been classiﬁed into two subtypes
(namely, P1 receptors (or adenosine receptors) and P2
receptors) based on their molecular cloning and pharma-
cological properties [25–28]. Adenosine and its phosphates,
ATP and ADP, have been identiﬁed as the endogenous
ligand for P1 and P2 receptors, respectively. Four subtypes
of metabotropic P1 receptors have been cloned and named
A 1 ,A 2 A ,A 2 B ,a n dA 3[ 25, 27]. The P2 receptors exist
in two major families: ionotropic (P2X receptors) and
metabotropic (P2Y receptors) [26–30]. Currently, there are
at least 7 cloned P2X receptors and at least 8 cloned P2Y
receptors [15–18, 21, 25–30]. P2X receptors are mainly
activated by ATP and its analogs, whereas P2Y receptors
can be activated by ATP, UTP, and UDP, depending on the
subtypes of P2Y receptors involved [15–18, 21, 25–30]. Most
of these receptors are capable of mediating responses to
several nucleotides, resulting in multiple receptors having
overlapping ligand preferences. In addition, distribution of
these receptors varies among diﬀerent tissues [15–18, 21, 25–
30]. Therefore, purinergic signaling is complicated. In this
section, we will describe reports suggesting that Up4Aa ﬀects
vascular tone and discuss the relevant mechanisms involved
in Up4A responses.
2.1. Aorta (Rat). Linder et al. [31] characterized the eﬀect
of Up4A in thoracic aorta from rats using isometric tension
recording. In intact aortic rings precontracted with phenyle-
phrine, Up4A treatment led to a modest endothelium-
dependent relaxation. On the other hand, under basal
conditions, Up4A induced a concentration-dependent con-
traction. This contraction was potentiated by endothelium
denudation or nitric oxide synthase (NOS) inhibition sug-
gesting that EDRF (mainly NO) constitutively suppresses
Up4A-induced contraction in thoracic aorta. Linder et al.
[31] further found that Up4A-induced contraction was
suppressed by P1 (8-PST [32]) or P2X (NF279 [33]) receptor
antagonists, L-type Ca2+ channel blockade (nifedipine [34]),
and Rho-kinase inhibition (Y27632 [35]). These results
suggested that Up4A-induced contraction is modulated by
NO, mediated by P1 and P2X receptor activation, and
involves L-type Ca2+ channels and Rho-kinase activation
in smooth muscle cells. Moreover, Up4A-induced contrac-
tion was attenuated by a membrane permeable superoxide
scavenger (tempol) and by an NADPH oxidase inhibitor
(apocynin) suggesting that superoxide generation aﬀects
Up4A-induced contractile responses [31].
2.2.PulmonaryArtery(Rat). Guietal.[36]characterizedthe
eﬀectof Up4A in pulmonary artery from rats using isometricAdvances in Pharmacological Sciences 3
Table 1: Up4A and vascular reactivity.
Artery/tissue Animal Response Putative receptor Signaling Reference








Pulmonary artery Rat Contraction P2Y Ca2+ (extracellular and
intracellular stores) [36]
Thoracic aorta Mouse Contraction
Relaxation [41]












arterioles Mouse Contraction [38]
NO: nitric oxide. Details are shown in the text.
tension recording and investigated the signaling mechanisms
related to Up4A responses. Up4A induced concentration-
dependent contraction of isolated rat pulmonary arteries.
Up4A was as potent as UTP and UDP in endothelium-
denuded arteries, while much more eﬀective than UTP
and UDP in endothelium-intact preparations [36]. Up4A-
inducedcontractionwasblockedbysuramin,butnotbyP2X
receptorantagonist(Ip5I)ordesensitizationofP2Xreceptors
with α,β-methylene-ATP [36]. Up4A -induced contraction
was inhibited by pretreatment with an inhibitor of Ca2+
release from sarcoplasmic reticulum (thapsigargin), a Ca2+
channel blocker (nitrendipine) and a Ca2+ chelator (EGTA),
but unaﬀected by a Rho-kinase inhibitor (H-1152) [36].
Moreover, unlike ATP and UTP, Up4A does not induce
vasodilation of endothelium-intact preparations contracted
with phenylephrine [36]. These results suggest that Up4A
is a potent vasoconstrictor, but not a vasodilator in the
rat pulmonary artery, and such contraction is mainly via
a suramin-sensitive P2Y receptor. The contractile eﬀect of
Up4A involves the entry of extracellular Ca2+ and release of
Ca2+ from intracellular stores but not Ca2+ sensitization due
to the activation of RhoA/Rho kinase pathway in vascular
smooth muscle cells. Therefore, Up4Ap o t e n t i a l l yp l a y sa n
important role in the regulation of pulmonary vascular tone.
2.3. Renal Artery (Rat and Mouse). Jankowski et al. [14]
observed that in rat isolated perfused kidney, Up4As t i m u -
lated vasoconstriction mainly via P2X1 receptors and proba-
bly also via P2Y2 and P2Y4 receptors. Very recently, ﬁndings
fromthissamegroupindicatethatintheratperfusedkidney,
in addition to smooth muscle P2X1 receptor-mediated
vasoconstriction, Up4A showed concentration-dependent
P2Y2 receptor-mediated, long-lasting vasoconstriction [37].
Moreover, they demonstrated that Up4A-induced vasocon-
striction was followed by vasodilation mediated by P2Y1 and
P2Y2 receptor activation on endothelial cells leading to the
release of NO [37].
In mouse vessels, Up4Aa c t sa sas t r o n gv a s o c o n s t r i c t i v e
mediator on aﬀerent arterioles, but has no signiﬁcant
eﬀect on the tone of eﬀerent arterioles [38]. The selective
preglomerular vasoconstrictor activity of Up4Am a yb ed u e
to the lack of P2X1 receptors, which are the main target of
Up4A, in postglomerular arterioles [39]. Therefore, it may be
assumedthatUp4Acontributestotheregulationofglomeru-
lar perfusion, intraglomerular pressure, and glomerular
ﬁltration rate. Moreover, Up4A was synthesized/secreted not
only by the endothelium but also by renal tubular cells.
Stimulation of tubule cells with oleoyl-2-acetyl-sn-glycerol
(OAG, protein kinase C activator) increases the release rate
of Up4A from tubule cells approximately 10-fold [38]. The
release of Up4A from renal tubular cells may aﬀect renal
perfusion. Up4A release may further contribute to renal
vascular autoregulation mechanisms [19, 40].
These results suggest that Up4A may play an important
role in renal haemodynamics and blood pressure regulation.
2.4. Aorta (Mouse). Hansen et al. [41] characterized the
eﬀects of Up4A in aorta from mice using isometric ten-
sion recording and in vivo arterial pressure measurements
in conscious mice and rats (see below). Up4Ah a sb o t h
relaxing and contracting eﬀects depending on the Up4A
concentration, the presence of precontraction, and the
mode of stimulation (namely, single versus cumulative
dose/concentrations). Up4A produced contraction in mouse
aorta. In rings precontracted with phenylephrine, Up4A
induced relaxation. A pronounced transient contraction
was observed when 10
−5 MU p 4Aw a sa d d e da sab o l u s ,
while vasodilation was predominant when Up4Aw a sa d d e d
cumulatively. The contraction induced by low concentra-
tions of Up4A was abolished by a cyclooxygenase inhibitor
(indomethacin), suggesting that Up4A-induced contraction
may be attributable to cyclooxygenase metabolites. There-
fore, Up4A can evoke both relaxation and contraction in
mouse aorta as well as rat aorta [31].4 Advances in Pharmacological Sciences
2.5. Up4AA ﬀects Arterial Blood Pressure In Vivo (Rat and
Mouse). Jankowskietal.[14]investigatedtheeﬀectsofUp4A
on mean arterial pressure of rats. Both noradrenaline and
Up4A increased mean arterial pressure when injected intra-
aortically in the anesthetized rat. Although noradrenaline
evoked a sharp, short-lasting increase in arterial blood pres-
sure, the same amount of Up4A showed a more prolonged
eﬀect on arterial blood pressure.
Hansen et al. [41] determined the eﬀects of Up4Ao n
mean arterial pressure in conscious mice and rats. Intra-
venous infusion of increasing doses of Up4A to unrestrained
miceandtoconscious,trainedratscausedadecreaseinmean
arterial pressure at higher rates of administration concomi-
tant with a marked antinatriuretic eﬀect. The discrepancy
between the two studies may be explained by diﬀerences
between the methodologies (namely, unconscious versus
conscious) and by diﬀerences in the administration of
Up4A (namely, single dose versus step-up doses). Future
experiments need to be performed to address this question.
Table 1 and Figure 1 summarize Up4Ae ﬀects on various
arteries from diﬀerent species.
3. Up4A andPathophysiological States
There is evidence that Up4A might have implications in
the pathogenesis of human arterial hypertension. Jankowski
et al. [42] demonstrated that the plasma concentrations
of Up4A are increased in juvenile hypertensive humans
compared with normotensive subjects. Up4A concentration
signiﬁcantly correlates with the left ventricular mass and
intima/media wall thickness in the hypertensive patients
[42]. Therefore, Up4A may have an association with hyper-
tension and hypertension-related vascular abnormalities.
As mentioned above, so far, the studies of Up4A-
mediated responses have been carried out only in normal
animals, and there is no study to indicate the vascular
eﬀects of Up4A under pathophysiological conditions, such
as arterial hypertension. Since the vascular responsiveness to
Up4A in hypertensive states remains unexplored/unknown,
we [43] recently addressed this issue using deoxycorticos-
terone acetate-salt (DOCA-salt) rats, a well-known salt-
dependent experimental model of arterial hypertension
[44–47]. Using isometric tension recording (myograph),
we observed that Up4A produced concentration-dependent
contractions in segments of renal and pulmonary arteries
at basal resting tension [43]. In DOCA-salt rats [versus
its control uninephrectomized (Uni) rats], Up4A-induced
contraction was similar in pulmonary artery and greater in
renal artery [43]. Up4A-induced contraction in renal artery
from both DOCA-salt and control groups was inhibited by
a nonselective P2 receptor antagonist (suramin) but not
by a P2X receptor antagonist (Ip5I). Furthermore, selective
P2Y2 agonist-(2-Thio-UTP-), P2Y2/P2Y4 agonist-(UTPγS-),
and P2Y6 agonist-(MRS2693-) induced contractions were
all increased in renal artery from DOCA-salt rats. Renal
arterialproteinexpressionofP2Y2,P2Y 4,andP2Y 6 receptors
was similar between the two groups. The extracellular signal
regulated kinase (ERK) pathway plays important roles in
the regulation of vascular tone [46, 48–50], and it has been
demonstrated that P2Y receptor activation can induce ERK
pathway activation [18, 28, 51]. In DOCA-salt renal artery,
the enhanced Up4A-induced contraction was reduced by an
ERKpathwayinhibitor(PD98059),andERKactivationstim-
ulated by Up4A was enhanced in renal artery from DOCA-
salt rats. Enhanced P2Y receptor signaling and activation
of the ERK pathway represent likely mechanisms mediating
the augmented Up4A-induced contraction in renal artery
from DOCA-salt hypertensive rats. Moreover, we recently
observed that, in DOCA-salt rats (versus Uni rats), Up4A-
induced contraction was increased in basilar and femoral
arteries, was decreased in small mesenteric artery, and was
unchanged in thoracic aorta [52]. These results suggest
that Up4A-induced contraction is heterogeneously aﬀected
among several vascular beds in DOCA-salt hypertensive
rats. These results indicate that abnormal Up4A-induced
contraction may be associated with the vascular dysfunction
seen in hypertension.
Jankowski et al. [42] also found that Up4Ac o u l d
lead to proliferation of human vascular smooth muscle
cells (VSMCs). This cell-cycle-dependent process involves
stimulation of S phase entry, and is due to the activation
of P2Y receptor rather than P2X receptor. Very recently, Gui
et al. [53] also suggested that Up4A stimulated proliferation
of VSMCs via activation of P2Y receptors and the PI3-
kinase/Akt and mitogen-activated protein kinase (MAPK)
pathways. Since increased proliferation of VSMCs reﬂects
not only on intima/media wall thickness but also on
atherogenesis [54–57], Up4A may play a potential role in the
development of atherosclerosis.
Schuchardt et al. [58] investigated the inﬂuence of
Up4A on formation of monocyte chemoattractant protein-
1 (MCP-1), which is an important early component of
the inﬂammatory response in atherosclerosis and induced
by oxidative stress [56, 59–61]. The authors also char-
acterized the underlying signaling transduction mecha-
nisms in rat VSMCs. Up4A induced MCP-1 expression
and secretion in VSMCs through the activation of P2Y2
receptor in a concentration-dependent manner. MCP-1
f o r m a t i o nd e p e n d e do ng e n e r a t i o no fR O S .U p 4A-induced
MCP-1 formation was suppressed by NAD(P)H oxidase
inhibitors (apocynin and diphenyl-iodonium) and by siRNA
against NOX1 (a component of NAD(P)H oxidase [62–64]).
Moreover, Up4A stimulated Rac1 activation and p47phox
translocation from cytosol to the plasma membrane (these
processes are required for assembling and activation of
NOX). The activation of MAPKs (i.e., ERK1/2 and p38
MAPK) is essential for Up4A-mediated intracellular signal
transduction [58]. These results clearly demonstrated that
Up4A induces NOX1-dependent ROS production, which
further stimulates MCP-1 formation through MAPK phos-
phorylation in VSMCs. This process requires the activation
of P2Y2 receptor. Thus, Up4Ai sn o to n l yap o t e n tE D C F
butalsoapotentinducerofproinﬂammatoryresponseinthe
vascular wall.
Moreover, Up4A has a stimulatory eﬀect on the oxidative
burst response (ROS production) of nonstimulated and
N-formyl-methionine-leucine-phenylalanine-(fMLP-) acti-
vated monocytes as well as after phorbol 12-myristateAdvances in Pharmacological Sciences 5
13-acetate (PMA) stimulation of both monocytes and lym-
phocytes [65]. Chronic inﬂammation in chronic kidney
disease or atherosclerosis is associated with oxidative stress,
and leukocytes are an important source of ROS [56, 57,
66]. Up4A potentially has impact on the initiation and
progression of vascular inﬂammatory diseases and may
represent a linking between blood pressure regulation and
atherosclerosis.
4. Conclusions
The present work reviews reported studies on the eﬀects of
Up4A on vascular function in physiological and pathophys-
iological states. Although Up4A deﬁnitely has an important
role in vascular function, some questions currently remain
unresolved. For instance, what are the mechanisms of
synthesis and catabolism of Up4A? To what extent are
there regionally diﬀerences in Up4A kinetics? Are there
mechanisms modiﬁed in vessels under physiological and
pathophysiological states? How and to what extent do Up4A
receptor(s) interact with Up4Ap u t a t i v ed e g r a d a t i o nf o r m s
(e.g., mononucleotides and nucleotides) in the vascular
system? How do the vascular actions of Up4A change
during aging? Are there sex diﬀerences in the response to
the dinucleotide? Since ion channels (e.g., P2X receptor)
and G protein-coupled receptor (e.g., P2Y receptor and
adenosine receptor) participate in multiprotein complexes
with signaling molecules and other receptors (dimerized
receptor or unknown Up4A speciﬁc receptor) should also be
investigated in physiological and pathophysiological states.
A comprehension of the vascular eﬀects of Up4A in other
cardiovascular diseases, such as atherosclerosis, diabetes, and
stroke should also be encouraged.
A better understanding of the role of Up4A on vascular
function and the regulation of Up4A signaling may provide
new insights into the mechanisms responsible for cardio-
vascular diseases and ultimately lead to novel therapeutic
strategies with the potential to improve of prognosis of
cardiovascular diseases.
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